Voluntary Recall of Some H1N1 Pediatric Vaccine – Open Access Healthcare

As part of its quality assurance program, the manufacturer, Sanofi Pasteur, performs routine, ongoing stability testing of its influenza A (H1N1) vaccine after the vaccine has been shipped to providers. Stability testing means measuring the strength (also called potency) of a vaccine over time. It is performed because sometimes the strength of a vaccine can go down over time. On December 7, Sanofi Pasteur notified CDC and FDA that the potency in one batch (called a “lot”) of pediatric syringes that had been distributed was later found to have dropped below a pre-specified limit. As a result of this finding, Sanofi Pasteur tested additional lots and found that three other lots that had been distributed also had an antigen content that, while properly filled at the time of manufacturing, was later measured to be below pre-specified limits. This means that doses from these four vaccine lots no longer meet the manufacturer’s specifications for potency. Sanofi Pasteur will send providers directions for returning any unused vaccine from these lots.

Read full story via Voluntary Recall of Some H1N1 Pediatric Vaccine – Open Access Healthcare.

Short URL: http://www.news.synavista.com/?p=6953

Posted by admin on Dec 15 2009. Filed under Health News. You can follow any responses to this entry through the RSS 2.0. Both comments and pings are currently closed.